CORT - CORCEPT THERAPEUTICS INC

QQQ $ 439.55 $ -0.26 (-0.06 %)

DIA $ 390.50 $ 1.74 (0.45 %)

SPY $ 517.10 $ 0.05 (0.01 %)

TLT $ 90.18 $ -0.55 (-0.61 %)

GLD $ 213.58 $ -0.63 (-0.29 %)

Previous Close

$ 25.4

Open

$ 24.50

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 23.92 - $ 25.50

52 Week Range

$ 20.84 - $ 34.28

Volume

932,663

Average Volume

Market Cap

2.79B

Beta (5Y Monthly)

$ 0.42

PE Ratio (TTM)

$ 23.82

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-01-2024	03-31-2024	10-Q
2	02-15-2024	12-31-2023	10-K
3	11-01-2023	09-30-2023	10-Q
4	08-02-2023	06-30-2023	10-Q
5	05-03-2023	03-31-2023	10-Q
6	02-28-2023	12-31-2022	10-K
7	11-03-2022	09-30-2022	10-Q
8	08-03-2022	06-30-2022	10-Q
9	05-05-2022	03-31-2022	10-Q
10	02-15-2022	12-31-2021	10-K
11	11-03-2021	09-30-2021	10-Q
12	07-29-2021	06-30-2021	10-Q
13	05-06-2021	03-31-2021	10-Q
14	02-23-2021	12-31-2020	10-K
15	11-03-2020	09-30-2020	10-Q
16	08-04-2020	06-30-2020	10-Q
17	05-04-2020	03-31-2020	10-Q
18	02-24-2020	12-31-2019	10-K
19	11-07-2019	09-30-2019	10-Q
20	08-01-2019	06-30-2019	10-Q
21	05-09-2019	03-31-2019	10-Q
22	02-26-2019	12-31-2018	10-K
23	11-02-2018	09-30-2018	10-Q
24	08-09-2018	06-30-2018	10-Q
25	05-09-2018	03-31-2018	10-Q
26	02-28-2018	12-31-2017	10-K
27	11-03-2017	09-30-2017	10-Q
28	08-02-2017	06-30-2017	10-Q
29	05-02-2017	03-31-2017	10-Q
30	03-06-2017	12-31-2016	10-K
31	11-02-2016	09-30-2016	10-Q
32	08-03-2016	06-30-2016	10-Q
33	05-04-2016	03-31-2016	10-Q
34	03-10-2016	12-31-2015	10-K
35	11-06-2015	09-30-2015	10-Q
36	08-07-2015	06-30-2015	10-Q
37	05-08-2015	03-31-2015	10-Q
38	03-13-2015	12-31-2014	10-K
39	11-07-2014	09-30-2014	10-Q
40	08-08-2014	06-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

The Analyst Verdict: Corcept Therapeutics ...
05/02/2024 20:01:04

HC Wainwright & Co. Maintains Buy on Corce...
05/02/2024 17:33:44

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises th...

Truist Securities Maintains Buy on Corcept...
05/02/2024 13:13:52

Truist Securities analyst Joon Lee maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from ...

Corcept Therapeutics Increases FY24 Revenu...
05/01/2024 20:19:56

Corcept Therapeutics Q1 EPS $0.25 Beats $0...
05/01/2024 20:10:24

Corcept Therapeutics (NASDAQ:CORT) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of ...

Corcept Completes Enrollment In Phase 4 CA...
04/29/2024 12:07:19

HC Wainwright & Co. Reiterates Buy on Corc...
04/23/2024 17:28:45

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Corcept Therapeutics (NASDAQ:CORT) with a Buy and maintain...

mid-cap-corcept-therapeutics-reveals-data-from-hormonal-disorder-study-fda-application-submission-expected-this-quarter

Mid-Cap Corcept Therapeutics Reveals Data ...
04/22/2024 16:36:10

Insights from Corcept Therapeutics' Phase 3 GRACE trial results for endogenous Cushing's syndrome. Discover rapid impro...

Corcept Therapeutics Says Patients In The ...
04/22/2024 12:03:08

Corcept Announces Results From Open-Label ...
04/22/2024 12:03:04

Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medicat...

Corcept Completes Enrollment In Phase 2 DA...
04/15/2024 12:09:00

Corcept Completes Enrollment In Pivotal Ph...
04/08/2024 12:05:10

Corcept Completes Enrollment In Phase 3 Gr...
04/01/2024 12:11:03

Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medicat...

whats-going-on-with-stress-hormone-modulator-focused-corcept-therapeutics-stock-friday

What's Going On With Stress Hormone Modula...
02/16/2024 16:25:17

Findings of Corcept Therapeutics' CATALYST study on Cushing's syndrome & difficult-to-control type 2 diabetes.

Corcept Announces Preliminary Results From...
02/15/2024 21:25:32

Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medicat...

Recap: Corcept Therapeutics Q4 Earnings
02/15/2024 21:15:17

Corcept Therapeutics Reiterated FY24 Reven...
02/15/2024 21:14:57

Corcept Therapeutics Q4 2023 GAAP EPS $0.2...
02/15/2024 21:09:52

Corcept Therapeutics (NASDAQ:CORT) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of ...

Earnings Scheduled For February 15, 2024
02/15/2024 10:17:01

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on rev...

Earnings Preview: Corcept Therapeutics
02/14/2024 16:01:39